Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
April 29 2022 - 09:23PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, will
hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to
review the topline results from the Saturn-2 Phase 3 trial for
TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of
Demodex blepharitis and provide a brief corporate update.
Webcast Information
The webcast can be accessed at the events section of the Tarsus
website. After the live webcast, the event will remain archived on
the Tarsus website at https://ir.tarsusrx.com/ for 90 days.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care. It is
advancing its pipeline to address several diseases with high unmet
need across a range of therapeutic categories, including eye care,
dermatology, and infectious disease prevention. The company is
studying two investigational medicines in clinical trials. Its lead
product candidate, TP-03, is a novel therapeutic being studied in a
second Phase 3 pivotal trial for the treatment of Demodex
blepharitis. TP-03 is also being developed for the treatment of
Meibomian Gland Disease. In addition, Tarsus is developing TP-05,
an oral, non-vaccine therapeutic for the prevention of Lyme
disease, which is currently being studied in a Phase 1b clinical
trial.
Contacts: Media Contact:Adrienne KempSr.
Director, Corporate Communications(949)
922-0801akemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2023 to Mar 2024